Results 201 to 210 of about 171,635 (309)

Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) and cannabigerol (CBG) alleviate hepatic steatosis in obese mice by shifting energy buffering towards phosphocreatine and enhancing lysosomal lipid degradation and trafficking. These effects are associated with increased creatine kinase activity and lysobisphosphatidic acid (LBPA) levels, highlighting a previously unrecognised ...
Radka Kočvarová, Shahar Azar, Bella Agranovich, Ifat Abramovich, Saveliy Kirillov, Alina Nemirovski, Saja Baraghithy, Inbar Plaschkes, Emmanuelle Merquiol, Alexander Rouvinski, Galia Blum, Liad Hinden, Joseph Tam   +12 more
wiley   +1 more source

Simvastatin combined with antiviral therapy for hepatitis B cirrhosis with portal hypertension: A case report. [PDF]

Medicine (Baltimore)
Zhang H, Li J, Zhou Y, Li X, Wang H, Gou W, Liu Z, Qi X.   +7 more
europepmc   +1 more source

Thrombospondin‐4 is upregulated in abdominal aortic aneurysm: A vasoprotective response with potential therapeutic relevance

British Journal of Pharmacology, EarlyView.
TSP4 is upregulated in human and experimental AAA. TSP4 knockdown accelerated AAA formation and exacerbated both vascular inflammation and remodelling, emphasizing that TSP4 upregulation may represent a protective response against AAA. Our findings suggest that preserving TSP4 could be a useful strategy in the clinical management of AAA.
Laia Blanco‐Casoliva, Lidia Puertas‐Umbert, Judith Alonso, Rafael Almendra‐Pegueros, Saray Varona, Mercedes Camacho, Gemma Arderiu, Lluís Asmarats, Marta Alegret, Jose Martinez‐Gonzalez, Cristina Rodriguez   +10 more
wiley   +1 more source

Case Report: Preoperative treatment of portal hypertension by splenic artery embolization for safe major hepatectomy: experience in three patients. [PDF]

Front Surg
Gürel D, Güzelbey T, Aydın O, Kaya S, Bostancı Ö, Özden İ.   +5 more
europepmc   +1 more source

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The American Diabetes Association recommends achieving treatment goals (glycated haemoglobin ≤ 53 mmol/mol [7.0%], blood pressure < 130/80 mmHg, low‐density lipoprotein cholesterol < 1.81 mmol/L and use of sodium–glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists), to reduce cardiovascular and kidney ...
João Sérgio Neves, Ana Rita Leite, Francisco Vasques‐Nóvoa, Bertram Pitt, Gerasimos Filippatos, Luis M. Ruilope, Peter Rossing, Stefan D. Anker, Gianluigi Savarese, Charlie A. B. Scott, Andrea Lage, Meike D. Brinker, João Pedro Ferreira   +12 more
wiley   +1 more source

DOACs reduce risk for new-onset portal hypertension in patients with cirrhosis and atrial fibrillation: A retrospective cohort study. [PDF]

Medicine (Baltimore)
Su Y, Wang J, Dong Q, Guan H, Ma C.
europepmc   +1 more source

A Collateral Venous Pathway in Omental Arch of Barkow After Spleen Preserving Distal Pancreatectomy

ANZ Journal of Surgery, EarlyView.
Cartanese Carmine, Scaramuzzi Matteo, De Luca Raffaele, Mastrandrea Giovanni, Sollitto Mario   +4 more
wiley   +1 more source

Comparative Predictive Value of Three Visceral Adiposity Indices for Cardiovascular Disease: A 17.5‐Year Korean Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiovascular diseases (CVD) are the leading cause of death worldwide, with excess visceral adipose tissue (VAT) being identified as an independent indicator of poor cardiovascular outcomes. We examined the association between three indices of VAT, namely, metabolic score for visceral fat (METS‐VF), visceral adiposity index (VAI), and ...
A‐Ra Cho, Seok‐Jae Heo, Taehwa Han, Yu‐Jin Kwon   +3 more
wiley   +1 more source

The pathophysiological role of portal hypertension in metabolic dysfunction-associated steatotic liver disease. [PDF]

Hepatol Commun
Møller S, Sjöstedt SMS, Hobolth L, Mortensen C, Mortensen C, Kimer N.   +5 more
europepmc   +1 more source

Diagnosis and management of equine metabolic syndrome

Equine Veterinary Education, EarlyView.
Summary Equine metabolic syndrome (EMS) is a prevalent endocrine disorder that increases the risk of hyperinsulinaemia‐associated laminitis (HAL), the most common and clinically significant form of laminitis. The central pathological feature of EMS is insulin dysregulation (ID), which encompasses basal or postprandial hyperinsulinaemia and tissue ...
F. R. Bertin
wiley   +1 more source